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Abstract 
Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful technique for 
studying bi-molecular interactions at the atomic scale. Our NMR lab is involved in the 
identification of small molecules, or ligands that bind to target protein receptors, such as 
tetanus (TeNT) and botulinum (BoNT) neurotoxins, anthrax proteins and HLA-DR10 
receptors on non-Hodgkin’s lymphoma cancer cells.  Once low affinity binders are 
identified, they can be linked together to produce multidentate synthetic high affinity 
ligands (SHALs) that have very high specificity for their target protein receptors. An 
important nanotechnology application for SHALs is their use in the development of 
robust chemical sensors or biochips for the detection of pathogen proteins in 
environmental samples or body fluids.    Here, we describe a recently developed NMR 
competition assay based on transferred nuclear Overhauser effect spectroscopy 
(trNOESY) that enables the identification of sets of ligands that bind to the same site, or a 
different site, on the surface of TeNT fragment C (TetC) than a known ‘marker’ ligand, 
doxorubicin. Using this assay, we can identify the optimal pairs of ligands to be linked 
together for creating detection reagents, as well as estimate the relative binding constants 
for ligands competing for the same site.    
 
Key words:  
Nuclear Magnetic Resonance, structure-based drug design, transferred nuclear 
Overhauser effect spectroscopy, tetanus toxin, biosensors 
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1. Introduction 
Nuclear Magnetic Resonance (NMR) spectroscopy has evolved into an important 
technique in support of structure-based drug design because of its long tradition in the 
study of molecular interactions [1, 2].  Several NMR experiments have been used in 
generic binding assays to identify weak, but specific, binding between small molecules 
and a target protein.  The advantage of these NMR screening methods is that they can be 
applied as soon as a target protein is available without the need for extensive assay 
development.  NMR screening methods have been reviewed extensively by others [3-5] 
and will not be described in detail here, with the exception of the transferred nuclear 
Overhauser effect spectroscopy experiment (trNOESY). 
TrNOESY experiments [6-8] are routinely used to detect ligand binding to a target 
protein under conditions of fast exchange (ligands that bind with mM to mM dissociation 
constants).  The advantages of the trNOESY method are that it does not require large 
amounts of pure, labeled protein, it is not limited by the size of the protein, and it can 
provide information about the structure of bound form of the ligand.  In the experiment, 
the intensity of each intra-ligand NOE crosspeak is governed by the population-weighted 
cross-relaxation rate [9] (Figure 1).   Thus the binding event is relatively straightforward 
to detect and does not require time-consuming chemical shift assignments. A strong 
negative NOE crosspeak is observed for binders, as opposed to weakly positive or zero 
NOE crosspeaks for the same compounds in the absence of the target receptor, as shown 
for MP-biocytin in Figure 2.  Thus the sign flip of the NOE cross peak between the free 
versus bound states acts as a simple binary filter to distinguish binders from nonbinders 
[10, 11] (see Note 1). 
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An important parameter in selecting a reagent for use in a sensor is its relative 
binding affinity.  Very recently, several labs, including our own, have begun to address 
the issue of whether NMR screening methods can simultaneously and rapidly provide this 
information [12-14].  For the preparation of multivalent ligands that consist of two or 
more ligands that are weak binders, it is also useful to determine if each ligand is binding 
with specificity to the same site or to a different site than another ligand.  Although the 
individual ligands that comprise a linked bidendate compound may only bind weakly to 
the protein, as expected because of their small size, the free energy of binding of the 
linked compound is, in principle, the sum of the free energies of each fragment plus a 
term due to linking [15]. Thus, linked compounds with < mM dissociation constants can 
be obtained by linking two fragments that each dissociate in the > mM range [16]. Here, 
we present the methods in detail, for carrying out a trNOESY competition binding assay 
for tetanus toxin fragment C (TetC). 
Tetanus toxin (TeNT) and the botulinum toxins (BoNTs) are structurally and 
functionally related members of the family of Clostridial neurotoxins. The recent interest 
in these neurotoxins arises from the increased frequency of BoNT’s use in medicine, 
occasional diary cattle and wildfowl deaths that have resulted from toxin ingestion and 
the potential threat that this protein might be used by terrorist groups or other nations as a 
biological weapon [17, 18]. Both toxins selectively concentrate at the synapse of axons in 
vertebrate motor neurons and are the most potent toxins known to man [19]. The entry of 
these toxins into neuronal cells requires the initial binding of the toxin to gangliosides on 
the cell surface. Thus effective inhibitors that block neuronal cell binding can be 
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developed for use as antidotes or serve as molecular recognition materials for affinity-
based chemical sensors that detect and identify these highly toxic proteins. 
 
2. Materials 
1. High field NMR instrument (≥ 500 MHz) (see Note 2) 
2. Available Chemical Directory or similar library of compounds to screen 
3. Recombinant tetanus toxin C fragment (TetC) (Roche Molecular Biochemicals, 
Indianapolis, IN) 
4. 100% Deuterium oxide (D2O) (Isotech Inc., Miamisburg, OH) 
5. 100% Deuterated dimethyl sulfoxide (DMSO) (Isotech Inc., Miamisburg, OH) 
6. Doxorubicin hydrochloride (Sigma-Aldrich Chemical Co., St. Louis, MO); 
Caution, the antitumor drug doxorubicin is an inhibitor of reverse transcriptase 
and RNA polymerase, is an immunosuppressive agent and it intercalates into 
DNA [20-22]. 
7. 3’-Sialyllactose (Sigma-Aldrich Chemical Co., St. Louis, MO) 
8. Sarcosine-Arg-Gly-Asp-Ser-Pro (Sar-RGDSP) (Sigma-Aldrich Chemical Co., St. 
Louis, MO) 
9. 3-(N-maleimidopropionyl)biocytin (MP-biocytin) (Sigma-Aldrich Chemical Co., 
St. Louis, MO) 
10. Lavendustin A (Sigma-Aldrich Chemical Co., St. Louis, MO); Caution, 
lavendustin A is a protein tyrosine kinase inhibitor [23]. 
11. Naphtho-fluorescein-di-b-galactopyranoside (NF-GalPyr) (Sigma-Aldrich 
Chemical Co., St. Louis, MO). 
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12. Ser-Gln-Asn-Tyr-Pro-Ile-Val (SQNYPIV) (Calbiochem-Novabiochem Corp., La 
Jolla, CA) 
13. Sialic acid ) (Calbiochem-Novabiochem Corp., La Jolla, CA) 
 
3. Methods 
The methods described below outline (1) the theory of the trNOE experiment, (2) the 
NMR experimental setup (3) NMR sample preparation, and (4) the combined 
screening/competition trNOESY assay.  
 
3.1. Theory of the Transferred Nuclear Overhauser Effect Experiment 
At spectrometer frequencies of 500-600 MHz (Hn), small molecules (MW < 1500 Da) 
in the free-state yield small, positive NOEs, while large protein molecules (MW > 10,000 
Da) yield large, negative NOEs. In the fast exchange regime (binding constant between 
10-3 and 10-7 M), the ligand acquires the NOE characteristics of the large molecule during 
the reversible binding and shows large negative NOEs (Figure 1). These characteristics 
are transferred from the bound state of the ligand to its free state, and therefore the ligand 
signals are still sharp due to the rapid total rotational correlation time, tc of the free 
ligand. The ligand binding event is thus identified by both the change in sign and the 
intensity buildup rate of its intramolecular NOEs. 
The theory behind the mechanism of trNOE has been well developed over the years 
[24-29]. The dynamics of the NOE is governed by the three species equilibrium process 
given by: 
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[P] + [L] 
offk
kon
¬
®   [PL],       [1] 
where,  [P], [L] and [PL] are the molar concentrations of the protein, the ligand and the 
complex, respectively, and kon and koff are the association and dissociation constants, 
respectively.  In the trNOE experiment, the exchange of the ligand between the free and 
bound states alters the relaxation dynamics of the ligand more significantly than of the 
protein. Under equilibrium conditions, the binding constant KD is the ratio of koff to kon.  
The exchange rate that is relevant to the NMR experiments, kex depends on the relative 
populations of the protein and ligand as well as the binding constant, and is defined as 
kex = kon[P] + koff = koff/(1-Lb),     [2] 
where, Lb is the bound ligand fraction. For a single ligand binding site, Lb is given by 
Lb = [(PT+LT+KD) – ( Ö(PT+LT+KD)2 – 4PTLT )]/2LT,   [3] 
where, PT and LT are the total protein and ligand concentrations, respectively, and KD is 
the binding constant. In the performance of trNOE experiments, it is useful to have the 
protein binding site at least half-saturated (LT » KD). This is accomplished by using a 
large molar excess of the ligand of approximately 5 to 50 times that of the protein. 
Exchange of the magnetization between the protein bound form and the free form of the 
ligand produces an averaged NOE.  
The exchange averaged NOE depends on the rate of exchange and the magnitude of 
the NOE between the free (NOEf) and bound (NOEb) forms. The exchange rate, kex, is 
considered fast, intermediate or slow if kex » |NOEf – NOEb|, kex » |NOEf – NOEb| and kex 
« |NOEf – NOEb|, respectively.  In the fast exchange regime (kex » |NOEf – NOEb|), the 
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trNOE experiments are extremely useful as the observed NOE is then a population 
weighted average. 
The dynamic interplay between the ligand intramolecular NOEs and the 
ligand/protein intermolecular exchange NOEs can be described by combining Solomon’s 
equations and chemical exchange equations [30-32]. Using this approach, Clore and 
Gronenborn described the observed effect of trNOE by using matrix notation [25, 26]. 
The combined matrix includes the pairwise interactions in a multiple-spin system 
undergoing exchange, which accounts for the spin diffusion effects as well [29, 33, 34]. 
The evolution of the intensity in a two dimensional trNOE experiment (trNOESY) is 
given by [30, 32]: 
( ) [4]                                               ,)( mm
md
d
tt
t
VΓV -=  
where tm is the mixing time, and the elements of the matrix V(tm ) are the measured peak 
volumes of the crosspeaks in the trNOESY spectrum, which are described in terms of the 
exchange-relaxation matrix G. The exchange rates (kex) as well as the self (rij) and cross 
relaxation (sij) rates of the various proton pairs are included in G . When the exchange is 
fast relative to the relaxation rates, the effective rate constants are molar fraction 
weighted averages of the rate constants of the free and bound forms. Thus, if ‘i’ and ‘j’ 
are the ligand spins, the effective cross relaxation rate sijavg is  
sijavg  = Lb sijb   + (1 – Lb) sijf .     [5] 
In this fast exchange limit, as pointed out by Landy and Rao [35], the relaxation + 
exchange matrix, G, can be symmetrized and thus the rate equation for the m-spin ligand 
and n-spin protein simplifies to a (n + m) differential equation [36]. The relative 
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concentrations of the ligand and protein, following Zabell and Post [37] and Eq.[2] can be 
written as:  
        
where, Glb and Glf  represent the symmetrical n ´ n relaxation matrices of the ligand in the 
bound and free forms, respectively  and Gpb and Gpf  have analogous definitions for the 
protein. The relative concentrations are defined by ‘m’ as  
     mbl = [PL]/([PL]+[L]), 
   mfl = [L]/([PL]+[L]), 
      mbp = [PL]/([PL]+[P]), 
mbl = [P]/([PL]+[P]).    [7]. 
These equations are generally used in cases where quantification of ligand crosspeaks 
in the trNOESY spectra is needed to determine the structure of the bound form of the 
ligand. This information is especially useful when combined with computational 
approaches in order to optimize models of protein/ligand complexes, which in turn are 
used to develop new ligands with higher affinity and specificity for the target site on the 
protein. 
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3.2 NMR Experimental Setup 
This section describes: (1) NMR pulse sequences, which are composed of a series of 
radio frequency pulses interspersed with delays, and are the actual NMR experiments, (2) 
the selection of the mixing time for the trNOESY experiment, and (3) experiment time 
and effects of temperature on the trNOESY experiment. 
 
3.2.1. NMR pulse sequences 
The pulse sequence for the trNOESY experiment differs slightly from the 
conventional three-pulse NOESY experiment [38], as shown in Figure 3.  
3.2.1.1.  Filtering out protein signals (see Note 3). 
One common modification is the insertion of a relaxation filter to suppress extraneous 
protein signals, which may interfere with the detection of the ligand signal. This can be 
achieved by the T1r (or R2) filter. This filter could either be introduced prior to or after 
the first 90° pulse. If introduced prior to the first pulse, then the filter needs to be flanked 
by additional 90° pulses or by using windowless multiple pulse sequences such as DIPSI 
[39], so that the magnetization is along the Z-axis after the filter is employed. If the filter 
is introduced after the first 90° pulse, as in the original experiment proposed by Scherf 
and Anglister [40], care must be taken to acquire the first t1 point to avoid the need for 
large phase corrections in the indirect dimension. 
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3.2.1.2. Suppression of the water signal (see Note 4). 
Another common modification to the pulse sequence is the control or suppression of 
the water magnetization. There are a variety of pre-experimental water suppression 
experimental schemes available, such as excitation sculpting based suppression [41] or 
WET [42, 43]. Post-experimental water signal elimination using methods such as water-
gate or its modifications [44, 45] are also a viable alternative to pre-elimination. When 
considering water suppression schemes in a trNOESY experiment, it is critical to 
consider how the water suppression will effect the detection of the ligand signals. For 
example, if the ligand contains exchangeable protons, then it is desirable to avoid 
presaturation as it tends to saturate these resonances as well. It is also important to note 
that all the post-experimental water suppression schemes (e.g. water-gate) have a non-
uniform excitation profile near the water frequency. Under such conditions, it is advisable 
to adjust the sample temperature to move the water signal so that any nearby ligand 
resonances do not get suppressed as well. 
 
3.2.2. Selection of Mixing times 
For screening purposes, it is first useful to identify where the ligand protons resonate 
when protein is not present.  This requires that a NOESY spectrum of the ligand be 
obtained. A direct comparison of the spectrum with ligand alone and the spectrum of the 
ligand or mixtures of ligands in the presence of the TetC protein provides a simple and 
rapid way of identifying those crosspeaks that belong to that particular ligand without 
having to assign the chemical shifts.  Assignment of chemical shifts can often be a very 
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time-consuming process, and would only be needed if the structure of the bound form of 
the ligand is to be determined. 
In the absence of protein, the NOESY experiments are carried out at longer (600 to 
900 ms) mixing times, while mixtures of ligands in the presence of TetC are carried out 
at shorter (200 and 300 ms) mixing times. Long mixing times are necessary for detection 
of NOEs for small molecules (< 1 to 2 kDa MW) because the product of wo (2p x 
spectrometer frequency) and tc (rotational correlation time) is less than 1 (wotc < 1); in 
contrast, shorter mixing times are required for large molecules or ligands binding to large 
molecules because wotc >> 1 [46]. 
 
3.2.3. Experiment time and Temperature Effects 
Typically, 300 increments are collected in t1, each with 48 or 64 scans and 1024 
complex data points collected in t2. Our NMR data were processed using the program 
vnmr (version 6.1C, Varian Inc., Palo Alto CA) and analyzed using the program FELIX 
(version 97, Accelrys, San Diego, CA).   
The time required for performing a trNOESY or NOESY experiment is dependent on 
the concentration of the ligands and the mixing time. For example, at concentrations of 
approximately 0.3 mM, 20 hrs are required for both the ligand alone (900 ms mixing 
time, 48 scans) and for the ligand in the presence of TetC (300 mixing time, 64 scans). At 
ligand concentrations of 1 mM, the time required can be reduced by half.  Collecting data 
on mixtures of ligands instead of single ligands further decreases the total time required 
for the trNOESY experiment. 
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In our studies, we arbitrarily chose to carry out the trNOESY experiments at either 20 
oC or 30 oC, empirically discovering that the data improved slightly at the higher 
temperature for most ligands. Changing the temperature can alter the rate of exchange 
between ligand and TetC to thereby increase the possibility for detection of trNOEs in 
some cases where binding was not observed.  Lower temperatures slow the exchange 
rate, while higher temperatures will increase the exchange rate. Thus, one way to address 
the important limitation of the trNOESY competition assay, which is that binding can 
only be detected for those compounds that have mM to mM dissociation constants, is to 
change the temperature and consequently the rate of exchange (see Note 5). 
 
3.3 Sample Preparation 
The methods used to (1) identify of the optimal set of ligands to screen, (2) prepare 
the protein and ligand stock solutions, and (3) prepare of the protein/ligand mixtures, are 
described below in Subheading 3.1.1-3.1.3. 
 3.3.1. Identification of the optimal set of ligands to screen for binding to TetC 
There are several strategies, including random screening of a suitable chemical 
database, which can be employed to identify sets of potential binders.  In this study, two 
crystal structures of TetC are available (pdb access codes 1AF9 and 1A8D [47, 48], 
(http://www.rcsb.org/pdb/)), so we employed a structure-based approach.  
3.3.1.1. Computational methods to identify suitable ligands 
The first step involved using the crystal structure of the protein to identify binding 
sites and to carry out a virtual screen of the Available Chemical Directory (ACD). Two 
surface binding sites, Site-1 and Site-2, are identified by calculating the solvent 
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accessible surface and using the SPHGEN routine from DOCK 4.01 [49], which packs 
clusters of spheres into structural pockets. A sphere-atom matching scheme in the DOCK 
4.01 program [50-52] is then used to computationally screen the ACD, which currently 
contains more than 300,000 commercially available compounds, and to predict which 
molecules will likely bind to Sites 1 and 2.  A variety of structurally diverse ligands are 
chosen to represent the spectrum of possible candidates, and the best candidates are 
ranked by energy and contact scores. The top 1000 compounds are then visually 
examined qualitatively to assess the interactions they form with the site.  
3.3.1.2. Further reduction and optimization of ligand set 
The next step is to further scale down the top 100 compounds obtained from the 
virtual screen to approximately 10-20 compounds for each site, using a selection criteria 
based on cost and availability. The final cut is made by checking the remaining 
compounds for binding activity by electrospray ionization mass spectroscopy (ESI-MS) 
[53, 54]. Although this step is not required, it does help to significantly speed up the 
process in narrowing down the number of likely candidates. The sequential funneling of 
300,000 ligands to about a dozen for each site resulted in optimizing the short list of 
compounds (Figure 4) to use in our NMR screening studies for binding activity in an 
aqueous environment. There are several reasons why checking for binding activity in 
solution is important. In particular, it is a prerequisite for identifying detection reagents 
that will be used in an aqueous environment. In addition, the synthesis of novel bidendate 
ligands requires that the individual compounds are compatible with one another and with 
TetC under similar solvent conditions. 
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3.3.2 Preparation of stock solutions and sample solutions. 
1. Store dry recombinant TetC at –15 to –25 oC (see Note 6). 
2. Dissolve 1-3 mg dry (lyophilized) TetC protein samples in 500 ml / 
experiment of 100% D2O to obtain a final concentration between 38 and 72 
mM. (see Note 7). 
3. Centrifuge at highest speed for 5 minutes to remove any insoluble material 
before adding ligands. 
4. Prepare concentrated stock solutions of ligands, either in 100 ml D2O or 
deuterated DMSO. The goal is to keep the total concentration of DMSO at or 
below 5% (v/v).  The addition of this small amount of DMSO would not be 
expected to affect the stability of the protein, as previously demonstrated by 
other NMR studies [16], but it should be checked experimentally for each 
protein by determining if the binding activity is still detectable for a known 
binder when the protein is in a 5% DMSO solution. Three ligands, MP-
biocytin, lavendustin A, and NF-galactopyranoside, were dissolved in 
deuterated DMSO; the remaining ligands (Figure 4) were all soluble in D2O. 
5. Calculate the volume of ligand stock solution required to prepare 
approximately 0.3 to 1 mM concentration in the final 500-600 mL sample 
volume. Test different molar ratios of TetC:doxorubicin ranging from 1:5 to 
1:50 in order to determine the best ratios for use in the experiments. (see Note 
8). 
6. Prepare protein/ligand complexes by one of two methods. (1) Dissolve 3 mg 
of TetC in 1.0 ml of D2O (57.9 mM) and centrifuged for 5 minutes in an 
UCRL-BOOK-203945 
 16
Eppendorf microcentrifuge at highest speed to remove insoluble material prior 
to adding the ligands. (2) Prepare mixtures of ligands in ~ 500 to 800 ml of 
D2O (0.2 to 1 mM) prior to the addition of 1 to 3 mg of dry TetC (38 to 72 
mM) to a final ratio of TetC:ligand of approximately 1:20.  
 
3.4 The Screening/Competition trNOESY Assay 
 Three screening/competition methods are described (1) sequential addition of 
ligands to TetC, (2) evaluation of ligands binding to TetC in reverse order, and (3) 
addition of TetC to different combinations of ligands for high throughput analysis. 
The trNOESY competition assay requires a ‘marker’ ligand, for which the binding 
site on the protein and preferably the binding constant are known. The crystal structures 
of BoNT/B ligand complexes show that doxorubicin [55] and 3’-sialyllactose [56] bind to 
Site-1 (Figure 5). Site-1 is a common surface feature found in the structures of both TetC 
and BoNT, and preliminary results obtained from the crystal structure of TetC in complex 
with doxorubicin indicate that doxorubicin also binds to Site-1 on TetC (S. Swaminathan, 
personal communication). Furthermore, the dissociation constant for the 
doxorubicin/TetC complex is known and is approximately 10 mM [57]. Doxorubicin is 
thus an ideal marker ligand to use in our study. 
The competition experiments are used to identify those compounds that bind to Site-1 
or a different site by determining if binding of doxorubicin to TetC is disrupted by a 
competing ligand binding to the same site.  This is evidenced by an absence of trNOEs 
for doxorubicin and the presence of trNOEs for the other ligand. However, it must be 
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stressed that these assays cannot identify the exact site of ligand binding, only if the sites 
are different or the same (see Note 9 for additional caveats).  
 
3.4.1 Method 1: Sequential Addition of Ligands.  
Sequential addition of each of the computationally predicted Site-2 ligands is used 
as a negative control to show whether any of these ligands will also bind to Site-1 by 
displacement of doxorubicin. The results also show whether two or more ligands can bind 
simultaneously to TetC, thus identifying suitable pairs of ligands to link together in 
developing the synthetic high affinity ligands (SHALs) as detection reagents for the 
Clostridium neurotoxins. 
1. Prepare a TetC:doxorubicin complex with the concentrations ~ [50 mM]/[1000 
mM] or ratio of 1:20. Collect trNOESY data 
2. Add ~ 1 mM of each of the predicted Site-2 ligand sequentially (Table 2), 
collecting trNOESY data after each addition.  
3. Analyze trNOESY data after each addition to determine whether crosspeaks 
belonging to doxorubicin or added ligand become weaker, positive or 
disappear indicating that doxorubicin has been displaced. The appearance of 
strong negative crosspeaks indicate that the ligand is able to bind 
simultaneously with doxorubicin and is thus a good candidate for linking to 
another ligand (Figure 6). 
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3.4.2. Method 2: Evaluation of ligands binding sequentially in reverse order to TetC. 
It is important to carry out the positive control, or the reverse experiment of Method 
1. That is each ligand shown in Figure 4 is first added to TetC in 20 fold access to 
determine if binding could be observed without the interference possible due to the 
presence of another ligand.  Doxorubicin is added next to the mixture to determine if it 
can displace the bound ligand being tested, and to confirm that the protein is active if no 
binding had occurred with ligand-1. If displacement occurs, than ligand-1 is identified as 
a Site-1 binder that exhibits a weaker binding affinity than the marker ligand, 
doxorubicin.  Next, another ligand, ligand-3, is added to determine if the ligand-1 or 
doxorubicin is displaced.  If ligand-1 is displaced but not doxorubicin, then ligand-1 and 
3 must compete for the same site, with the ligand-3 having the higher binding affinity.  A 
comprehensive analysis of the optimized short list of compounds using this strategy 
yielded the results shown in Figure 7.  A step-by-step example of the method is described 
below.  
1. Add 20 fold excess of sialic acid to TetC (Table 2) and acquire a 300 ms trNOESY 
spectrum (Figure 8A). Sialic Acid does not appear to bind. 
2. Add 20 fold excess doxorubicin to the sialic acid/TetC solution. Acquire a 300 ms 
trNOESY spectrum (Figure 8B) to confirm that the protein has not lost its activity or that 
the batch of protein used was bad. 
3. Add 20 fold excess of 3’-sialyllactose (another Site-1 binder) to the sialic 
acid/TetC/doxorubicin solution.  Acquire a 300 ms trNOESY spectrum.  In this case, 3’-
sialyllactose displaced doxorubicin, confirming that both ligands bind to Site-1, with 3’-
sialyllactose having a higher binding affinity constant than doxorubicin. 
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3.4.3. Method 3: Addition of TetC to Different Combinations of Ligands. 
This method screens multiple ligands simultaneously for binding to TetC in a more 
high throughput manner.  Up to ten ligands at a time can be rapidly screened, but since 
the set of ligands had been prescreened by computational and mass spectroscopy 
methods, we limited our combinations to three at a time, as shown in Figure 8. The time 
lost by running a larger number of trNOESY experiments is easily gained back by having 
to analyze much less complicated, and unambiguous, data sets.   The experimental results 
also provided key information about the compatibility of the ligands under the same 
solvent conditions.  
  
4. NOTES 
1. Negative NOE crosspeaks for small molecules in the absence of TetC were 
sometimes observed when the molecule contains protons attached to large ring 
systems, such as the protons attached to the four-ring system of doxorubicin.  These 
protons exhibit less internal motion than those located in more flexible long carbon 
chains. However, although the sign of the trNOE crosspeaks corresponding to these 
aromatic resonances remained the same regardless of whether TetC was present or 
not, their intensities were always much stronger for the bound ligand.  Thus, both the 
sign and intensity of the crosspeaks must be taken into consideration when 
distinguishing ligands that bind from those that do not. 
2. Our experiments were carried out on a Varian Inova 600 MHz spectrometer. 
Although the experiments can be carried out on a lower field instrument, higher 
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concentrations of both protein and ligands will be required because of the sensitivity 
of the experiment decreases with decreasing magnetic field strength. 
3. This step is only necessary if the protein concentration is high and/or the 
molecular weight of the protein is low.  Either case would result in the detection of 
protein signals that may interfere with the observation of the ligand signals. In our 
case, the TetC concentration is kept low (~ 50 mM). Although TetC signals could be 
detected at higher concentrations (~ 72 mM), they did not interfere with the detection 
of the ligand signals. In addition, the molecular weight of TetC is sufficiently large 
(51 kDa) and it is known to dimerize, so that the protein signals are broadened out 
into the baseline.  
4. If the ligands and proteins can be dissolved in deuterated solvents and buffers, 
then a simple presaturation pulse of the water signal can suffice to eliminate any 
residual water signal.  However, if the samples need to be prepared in solvents or 
buffers that contain a high ratio of H2O/D2O, then it is necessary to implement one of 
these water suppression schemes. 
5. Sialic acid did not bind TetC at 2, 10, 20, 30, or 37 oC, as evidenced by the 
presence of weak positive crosspeaks in the spectra at all of these temperatures.  
However, a crystal structure of a TetC/sialic acid complex by Emsley et al. [58] 
shows that sialic acid binds to a site that is adjacent to Site-1.  One possible 
explanation for the discrepancies between the NMR and x-ray results is that sialic 
acid binds TetC with < 103 M or > 106 M affinity in the temperature range we tested.  
Another reason, however, may be due to differences in binding between the crystal 
state and the solution state. 
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6. While TetC can be purchased as a dry, lyophilized powder, other proteins may not 
be available dried or they cannot be dried without comprising their activity or risking 
their precipitation.  In these cases, either the protein is dialyzed against deuterated 
buffer or the experiment is carried out in 90% H2O/10% D2O.  
7. The minimum volume needed for the NMR experiment in a standard 5 mm tube is 
approximately 500 ml. However, other NMR tubes and probes could be used instead 
to reduce the amount of sample needed in cases were the protein is rare or has limited 
solubility. For example, 5 mm Shigemi tubes (200-300 mL) or a microprobe (2 mL) 
can be used to reduce the volumes. However, it should be noted that these are more 
expensive options and not always available in every NMR lab.   
8. Ligand:Protein ratios between 5 and 50 can be used depending on the amount of 
protein available. The optimal molar ratio of TetC:doxorubicin was found to be 
between 1:15 and 1:25 and these ratios provided good sensitivity for detection of 
trNOEs for a large range of structurally unrelated ligands 
9. Several limitations of trNOESY competition assays need to be considered: The 
possibility that two or more ligands can bind the same site simultaneously can not be 
completely ruled out based only on their lack of competition.  Recently, Ma et al [59] 
have proposed that a protein can preexist in ensembles of sub-states, as a result of its 
conformational flexibility, and present a range of different binding site shapes to the 
incoming ligands, such that one site may recognize and bind multiple diverse ligands. 
An assumption has been made that the ligands are binding specifically to one site 
only, which may not always be the case.  For example, N-acetylgalactosamine binds 
to two different sites in the crystal structure of the TetC complex [58]. Similarly, if a 
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predicted Site-2 ligand is binding with specificity to more than one site, a stronger 
competitor can displace it from one site, but not necessarily from the other sites.  In 
such a case, both ligands would bind simultaneously to TetC. Non-specific 
association of a ligand with TetC is also possible, especially at very high 
concentrations of ligand. 
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Table 1. Ligands tested positive by ESI-MS for noncovalent complex formation with 
TetC  
 
Predicted Site-1 Predicted Site-2 
Doxorubicin1,2 Tyr-Glu-Trp  
3’-Sialyllactose2 Lavendustin A 
D-(+)-cellotetraose1 Sar-Arg-Gly-Asp-Ser-Pro 
Neohesperidin diHCl1 Naphthofluorescein di-(b-D-galactopyranoside) 
Gly-Arg-Gly-Asp-Ser1 3-(N-maleimidopropionyl) biocytin 
Hemorphin-51 Ser-Gln-Asn-Tyr-Pro-Ile-Val 
Etoposide phosphate  
1Reported in [57]. 2Binds Site-1 in BoNT/B [55] 
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Table 2.  Concentrations of Ligands and TetC and Observation of Binding Activity. 
 
Figure Ligand  [Lig] 
(mM) 
[TetC] 
(mM) 
[TetC]:[Lig] binding 
Figure 6 
A Doxorubicin 1081.4 54.3 1:20 yes 
B Sar-RGDSP 1116.3 50.6 1:22 no 
C SQNYPIV 1050.6 47.4 1:22 yes 
D Lavendustin A 993.3 45.0 1:22 yes 
E NF-GalPyr 926.6 43.3 1:21 maybe1 
Figure 8 
A Sialic acid 386.7 22.3 1:17 no 
BC Doxorubicin 365.6 21.5 1:17 yes,no2 
C 3’-Sialyllactose 351.9 20.7 1:17 yes 
1Precipitation was observed, resulting in a decrease in the intensities of all 
crosspeaks. 2Doxorubicin binding was observed in 8B but not in 8C. 
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Figures 
 
 
Figure 1: Principle of the experiment. The trNOE is only operative when the ligand 
is bound, since the ligand experiences a long correlation time (tc) only in the bound state. 
The NOE is transferred and measured on the resonances of the ligand in the free state. 
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Figure 2. The trNOESY experiment: (A) 900 ms NOESY spectrum of MP-biocytin 
(~ 1 mM) exhibits weak positive crosspeaks (in gray). (B) Addition of TetC (~ 0.05 mM) 
results in the MP-biocytin crosspeaks in the 300 ms trNOESY to flip their sign to 
negative (in black) and increase in intensity, indicating that MP-biocytin binds to TetC. 
Several of the crosspeaks in both spectra are designated by the dashed arrows and the 900 
ms spectrum in A is plotted at 2 times lower level than the 300 ms trNOESY spectra in B 
for presentation purposes. Spectra were acquired at 30 oC.  
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Figure 3. The trNOESY pulse sequence. Bars represent 90o radio-frequency pulses 
and FID stands for free induction decay. The pulses and the receiver are phase cycled to 
select the NOE and perform phase-sensitive detection along t1.  
 
 
 
 
UCRL-BOOK-203945 
 36
 
 
Figure 4. The structures and molecular weights of the ligands used in this study. The 
‘marker’ ligand, doxorubicin, is boxed. 
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Figure 5. Crystal structure of TetC with doxorubicin, the marker ligand, 
computationally docked into Site-1.  The figure was made using Molscript [60] and 
Raster3D [61] programs. 
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Figure 6. Effect of doxorubicin binding in Site-1 on predicted Site-2 ligands binding 
to TetC: Expanded regions of the 2D trNOESY spectra of TetC/ligand complexes at 200 
ms mixing time and 20 oC showing binding of (A) doxorubicin (Site-1 marker ligand). 
The arrows indicate one aliphatic and one aromatic crosspeak that belongs to 
doxorubicin, which remains bound throughout the sequential additions of (B) Sar-
RGDSP, (C) SQNYPIV, (D) Lavendustin A, and (E) NF-GalPyr.  The appearance of 
new, negative crosspeaks  in each panel are boxed, and indicate that Sar-RGRSP does not 
bind when doxorubicin is present but both SQNYPIV and lavendustin A do. The addition 
of NF-GalPyr (panel E), appears to partially displace lavendustin A, but not doxorubicin 
and SQNYPIV.  
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Figure 7. Grouping of optimized set of ligands tested by the trNOESY competition 
assay into three different binding sites on TetC. The lines indicate how a ligand from 
each site can be linked in unique ways to develop SHALs as detection reagents in 
nanosensors. Three ligands were eliminated because either binding was not detected or 
the ligand was insoluble in aqueous solutions. 
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Figure 8. 300 ms trNOESY spectra at 2 oC of (A) sialic acid, which does not appear 
to bind to TetC, as evidenced by weak and positive trNOEs (gray boxed crosspeaks); (B) 
the addition of doxorubicin to a mixture of TetC and sialic acid, which results in 
doxorubicin binding as evidenced by the strong negative trNOEs, (black circled 
crosspeaks); and (C) the addition of 3’-sialyllactose to the mixture of sialic acid, 
doxorubicin and TetC shows that 3’-sialyllactose displaces doxorubicin from binding in 
Site-1. The circled positions of doxorubicin crosspeaks from (B) and the boxed gray 
sialic acid crosspeaks are shown in (C) for comparison.   
 
 
